364,324 Shares in Caribou Biosciences, Inc. $CRBU Purchased by Green Alpha Advisors LLC

Green Alpha Advisors LLC purchased a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 364,324 shares of the company’s stock, valued at approximately $641,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Renaissance Technologies LLC grew its stake in shares of Caribou Biosciences by 58.0% in the 1st quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock worth $4,922,000 after purchasing an additional 950,640 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Caribou Biosciences during the second quarter valued at approximately $816,000. Invesco Ltd. lifted its stake in Caribou Biosciences by 187.2% during the fourth quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock valued at $56,000 after purchasing an additional 22,856 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in Caribou Biosciences during the second quarter worth approximately $30,000. Finally, Creative Planning bought a new stake in Caribou Biosciences during the second quarter worth approximately $25,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Bank of America decreased their price target on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Finally, HC Wainwright lifted their target price on Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

Caribou Biosciences Price Performance

CRBU stock opened at $1.66 on Friday. The firm has a market capitalization of $177.97 million, a P/E ratio of -1.54 and a beta of 2.38. Caribou Biosciences, Inc. has a 52-week low of $1.38 and a 52-week high of $3.54. The company’s 50 day simple moving average is $1.67 and its 200-day simple moving average is $1.84.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The firm had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Sell-side analysts predict that Caribou Biosciences, Inc. will post -0.88 EPS for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.